VivoSim Labs (NASDAQ:VIVS – Get Free Report) and Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.
Profitability
This table compares VivoSim Labs and Maravai LifeSciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VivoSim Labs | -11,016.07% | -612.23% | -177.02% |
| Maravai LifeSciences | -37.07% | -15.70% | -8.17% |
Valuation & Earnings
This table compares VivoSim Labs and Maravai LifeSciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VivoSim Labs | $112,000.00 | 22.89 | -$13.84 million | ($4.47) | -0.03 |
| Maravai LifeSciences | $185.74 million | 10.92 | -$130.77 million | ($0.52) | -15.02 |
VivoSim Labs has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
8.2% of VivoSim Labs shares are owned by institutional investors. Comparatively, 50.2% of Maravai LifeSciences shares are owned by institutional investors. 1.0% of VivoSim Labs shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
VivoSim Labs has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations for VivoSim Labs and Maravai LifeSciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VivoSim Labs | 1 | 0 | 0 | 0 | 1.00 |
| Maravai LifeSciences | 1 | 1 | 2 | 1 | 2.60 |
Maravai LifeSciences has a consensus price target of $7.38, indicating a potential downside of 5.57%. Given Maravai LifeSciences’ stronger consensus rating and higher possible upside, analysts plainly believe Maravai LifeSciences is more favorable than VivoSim Labs.
Summary
Maravai LifeSciences beats VivoSim Labs on 11 of the 15 factors compared between the two stocks.
About VivoSim Labs
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
Receive News & Ratings for VivoSim Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VivoSim Labs and related companies with MarketBeat.com's FREE daily email newsletter.
